Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.

Safety: ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg, with no discontinuations due to adverse events (AEs) or serious adverse events (SAEs) ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO ...

Shanghai Zhimeng Biopharma Inc. ( 'Zhimeng') announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

A research team has developed a new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor ...

Leiden researchers, led by Sebastian Pomplun, have developed a new method to screen hundreds of thousands of molecules for ...

Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy ...

Aldeyra Therapeutics reports positive results from phase 2 clinical trial in alcohol-connected hepatitis: Lexington, Massachusetts Thursday, October 30, 2025, 17:30 Hrs [IST] Alde ...